AiMIFY (1.x)
Overview
AiMIFY (1.x) is an AI-powered software developed by Subtle Medical and sold by Bracco, designed to significantly enhance Magnetic Resonance Imaging (MRI) of the brain. Contrary to a physician directory tool, AiMIFY focuses on improving the visualization of small and poorly enhanced lesions by selectively amplifying contrast enhancement in brain MRI scans. It can achieve up to double the visibility compared to standard post-contrast images acquired with FDA-approved gadolinium-based contrast agents (GBCAs). This technology integrates seamlessly into existing radiology workflows, sitting between the MRI scanner and the Picture Archiving and Communication System (PACS), and is compatible with any brand of MRI scanner. AiMIFY aims to provide radiologists and neuroradiologists with clearer, more detailed images, thereby enhancing diagnostic confidence.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven brain MRI enhancement
- Amplifies contrast enhancement up to 2x for GBCAs
- Improves visualization of small and poorly enhanced lesions
- Increases contrast-to-noise ratio (CNR)
- Increases contrast enhancement (CEP)
- Increases lesion-to-brain ratio (LBR)
- Vendor-neutral software solution
- Seamless integration into existing radiology workflow
- Compatible with all MRI scanner brands and PACS
Use Cases
- Enhancing diagnostic confidence in brain MRI reads
- Improving detection of small and poorly enhanced brain lesions
- Optimizing image quality for contrast-enhanced brain MRI
- Streamlining radiology workflows by providing clearer images
What Physicians Need to Know
AiMIFY-enhanced images should not be used alone for patient diagnosis; the standard post-contrast image must always be reviewed first. While it enhances lesion visibility and offers a potentially safer alternative to higher gadolinium doses, it is not intended for acquiring stat or emergent scans, as image processing time may delay diagnosis. Physicians should adhere strictly to the gadolinium-based contrast agent's instructions for use, including contraindications, precautions, and warnings for subpopulations, prior to processing with AiMIFY.
AiMIFY (1.x) is a software as a medical device (SaMD) that operates as a post-processing tool, meaning it does not directly interact with the MRI scanner. It is vendor-neutral and compatible with DICOM image datasets from various MRI scanner manufacturers, including GE Medical Systems, Philips Medical Systems, Siemens Healthineers, and Hitachi. The software is an exclusive collaboration between Bracco Diagnostics and Subtle Medical. It works seamlessly with existing PACS/workstations.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing — Not publicly available; contact Subtle Medical or Bracco for details |
| Deployment | Software (cloud or on-premise) integrated between scanner and PACS |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated AiMIFY (1.x) received FDA 510(k) clearance (K240290) to increase contrast-to-noise ratio (CNR), contrast enhancement (CEP), and lesion-to-brain ratio (LBR) of enhancing tissue in brain MRI images acquired with a gadolinium-based contrast agent. |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Neurosurgery, Radiology |
What the Web Says
AiMIFY (1.x) is an AI-powered software developed by Subtle Medical in collaboration with Bracco Diagnostics, designed to enhance contrast in brain MRI images. It has received FDA clearance as a Class II software as a medical device (SaMD) and is also CE marked (MDR). The software aims to improve the visibility of brain lesions, including small and poorly enhanced ones, potentially leading to more confident diagnoses and more efficient workflows.
Overall: PositiveStrengths
- Amplifies contrast enhancement in brain MRI images up to two times, improving lesion visibility.
- Aids radiologists and neuroradiologists in identifying lesions more clearly and confidently.
- Potentially reduces the need for higher gadolinium doses, contributing to patient safety and sustainable imaging practices.
- Enhances workflow efficiency and can reduce radiologist fatigue.
- Validated across diverse test data, including various patient demographics, pathologies, lesion sizes, scanner vendors, and MRI sequences.
- Integrates with existing clinical practice to improve patient care.
Limitations
- Performance is tied to scanner mix and protocols.
- Pricing is sales-led and scoped per buyer, not publicly posted.
- AiMIFY-enhanced images may contain false lesions due to enhancement of image quality issues or introduction by the algorithm; standard post-contrast images should be used for adjudication.
- Only trained and tested on head MRI for contrast enhancement; use in other anatomies or cases may result in unknown performance.
- In cases where vessel conspicuity interferes with or delays diagnosis, the standard post-contrast image should be used.
- Limited public reviews from physicians, healthcare IT, or tech reviewers specifically for AiMIFY (1.x) are available, making a comprehensive sentiment analysis challenging.
Based on reviews from: Subtle Medical Reviews, Pricing & Features | SoftFinders, AiMIFY enhancing medical imaging with AI - YouTube, Customer Testimonials - Subtle Medical, Bracco Diagnostics Inc. and Subtle Medical Announce FDA Clearance of AiMIFYu2122 Software for Enhanced MRI - PR Newswire, AiMIFY enhancing medical imaging with AI - Bracco, FDA Clears Emerging AI-Powered Software for Brain MRI | Diagnostic Imaging, Bracco launches AiMIFY in EU, announces Avicenna.AI collaboration - AuntMinnieEurope, AiMIFY - BraccoMR, AiMIFY Manuscript - Supplemental Material - medRxiv
Last updated: 2026-07-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AiMIFY (1.x)
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for AiMIFY (1.x).
No videos found. Search YouTube directly
Frequently Asked Questions
Investors who backed AiMIFY (1.x)
Funded through the company that built this tool.
